Ramsøe K, Andreasen P B, Ranek L
Scand J Gastroenterol. 1980;15(1):65-72. doi: 10.3109/00365528009181434.
The galactose elimination capacity and the plasma clearance of phenazone were investigated in 24 patients with uncomplicated acute hepatitis and in 8 patients who survived and in 26 who died of fulminant hepatitis. The galactose elimination capacity was 52% of the normal mean value on admission to the hospital in uncomplicated hepatitis, 47% in patients who survived fulminant hepatitis, and 22% in the fatal cases, while the plasma clearance of phenazone was 43%, 22%, and 10%, respectively. Both quantitative liver function tests showed rapid improvement in most cases of uncomplicated acute hepatitis and in the patients who survived fulminant hepatitis. They did not improve in the fatal cases of fulminant hepatitis, among whom the patients with the lowest initial values died first. Both the galactose elimination capacity and the plasma clearance of phenazone were significantly higher in survivors than in non-survivors of fulminant hepatitis. The results indicate that the loss of functioning liver cell mass is about 60-70% in the acute stage of uncomplicated hepatitis and 80-85% in patients who survive fulminant hepatitis, whereas patients who die of fulminant hepatitis have nearly total loss of functioning liver cell mass.
对24例无并发症的急性肝炎患者、8例暴发性肝炎存活患者以及26例暴发性肝炎死亡患者的半乳糖清除能力和非那宗的血浆清除率进行了研究。在无并发症肝炎患者入院时,半乳糖清除能力为正常平均值的52%,暴发性肝炎存活患者为47%,死亡病例为22%;而非那宗的血浆清除率分别为43%、22%和10%。两项肝功能定量检测显示,在大多数无并发症急性肝炎病例以及暴发性肝炎存活患者中,肝功能迅速改善。在暴发性肝炎死亡病例中肝功能未改善,其中初始值最低的患者最先死亡。暴发性肝炎存活者的半乳糖清除能力和非那宗的血浆清除率均显著高于非存活者。结果表明,在无并发症肝炎急性期,功能性肝细胞团损失约60 - 70%,暴发性肝炎存活患者为80 - 85%,而死于暴发性肝炎的患者功能性肝细胞团几乎完全丧失。